Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 714Carcinoma, Renal Cell 227Urinary Bladder Neoplasms 211Carcinoma, Transitional Cell 109Breast Neoplasms 99Kidney Neoplasms 96Neoplasms 88Carcinoma, Non-Small-Cell Lung 80Melanoma 79Ovarian Neoplasms 75Neoplasm Metastasis 69Colorectal Neoplasms 64Non-Muscle Invasive Bladder Neoplasms 56Lung Neoplasms 56Pancreatic Neoplasms 50Sarcoma 44Endometrial Neoplasms 42Stomach Neoplasms 40Uterine Cervical Neoplasms 36Adenocarcinoma 34Carcinoma, Hepatocellular 32Wilms Tumor 31Esophageal Neoplasms 30Squamous Cell Carcinoma of Head and Neck 27Triple Negative Breast Neoplasms 26Head and Neck Neoplasms 25Colonic Neoplasms 24Testicular Neoplasms 23Neuroblastoma 23Urologic Neoplasms 22

Interventions

darolutamide 1Pluvicto 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
High-Risk Localized Prostate Cancer × Genitourinary × 90 days × Clear all
NCT07450599 2026-05-13

CHINANEO

Bayer

Phase 2 Recruiting
250 enrolled
Genitourinary

High-Risk Localized Prostate Cancer

NCT07550517 2026-04-24

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Not yet recruiting
60 enrolled
Genitourinary

High-Risk Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡